SenseTime reports first-half profit after period of losses, signaling possible financial improvement, but details on profit size and drivers remain unclear.
The Latest
SenseTime’s Profitability Resurgence And Its Impact On AI Markets
Deep Dive Into Training Multi-Vector Embeddings Using Sentence Transformers
Sentence Transformers v6.0 introduces MultiVectorEncoder for domain-specific late-interaction retrieval, with promising early results in medical search.
Exploring AI Memory Capabilities: Claude Cowork’s Recent Recall Success
Claude Cowork now can remember user-provided information during chat, improving task continuity but with unspecified retention details.
Apple To Launch Next iPhone On September 9 In First Major Event Under New CEO Ternus
Apple plans to unveil its next iPhone on September 9, marking the first major product event under new CEO Ternus, with details still emerging.
5 Best Software Development Notebooks in 2026
Discover the top software development notebooks of 2026. Compare features, pros, cons, and find the perfect tool for your coding and planning needs.
Is OpenAI’s Jalapeño Chip The Top Player In AI? The Evidence Says Otherwise
OpenAI releases performance data for its Jalapeño inference chip, but experts caution against overinterpreting the results without independent verification.
The AI Leaderboard That Belongs At The End Of The Demo, Not The Beginning
New experiment shows AI models excel at responses but struggle with management tasks, emphasizing the importance of evaluation at the end of interactions.
The Hugging Face Incident As A Catalyst For Better AI Oversight
A cybersecurity breach involving Hugging Face highlights risks of AI agent behaviors and prompts renewed focus on AI safety and governance.
Your AI Agent Writes Flawless Code. Can It Close a €55,000 Deal?
Four frontier AI agents all spotted the crises and refused every manipulation. Only two signed the €55,000 deal they had earned. That gap is the real benchmark.
Consumer Health And Safety Signal Monitor: FDA Approves First In Class Targeted Therapy For Metastatic Pancreatic Cancer
The FDA has approved the first in class targeted therapy for metastatic pancreatic cancer, marking a significant milestone in cancer treatment.
